Pivotal bioVenture Partners Investment Advisor LLC — 13F Holdings & Portfolio
CIK 1844645 · latest 13F-HR filed 2026-08-13
Pivotal bioVenture Partners Investment Advisor LLC manages $307.8M in 13F-reported U.S. long-equity assets across 13 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PCVX (26.92%), ARQT (10.78%), TRVI (10.56%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position and exited 1; 7 existing positions rose in reported value and 2 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-13
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- TREVI THERAPEUTICS INC$14.0M +75.3%
- MAPLIGHT THERAPEUTICS INC$9.5M +76.3%
- BIOAGE LABS INC$4.6M +40.1%
- AVALO THERAPEUTICS INC$3.6M +81.5%
- RALLYBIO CORP$2.1M +78.4%
Pivotal bioVenture Partners Investment Advisor LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | VAXCYTE INC | PCVX | 92243G108 | $82.9M | 26.92% | 1,425,470 | SH |
| 2 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $33.2M | 10.78% | 1,265,283 | SH |
| 3 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $32.5M | 10.56% | 1,742,672 | SH |
| 4 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $31.8M | 10.34% | 966,792 | SH |
| 5 | EVOMMUNE INC | EVMN | 30054Y107 | $25.6M | 8.32% | 1,926,943 | SH |
| 6 | MAPLIGHT THERAPEUTICS INC | MPLT | 56565P103 | $21.9M | 7.12% | 611,446 | SH |
| 7 | OCULIS HOLDING AG | OCS | H5870P102 | $20.9M | 6.79% | 1,506,250 | SH |
| 8 | BIOAGE LABS INC | BIOA | 09077V100 | $16.0M | 5.20% | 653,374 | SH |
| 9 | IMMUNOME INC | IMNM | 45257U108 | $15.5M | 5.04% | 732,512 | SH |
| 10 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $12.5M | 4.05% | 490,766 | SH |
| 11 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $8.0M | 2.61% | 434,033 | SH |
| 12 | RALLYBIO CORP | RLYB | 75120L209 | $4.8M | 1.56% | 300,579 | SH |
| 13 | RECURSION PHARMACEUTICALS IN | RXRX | 75629V104 | $2.2M | 0.71% | 595,518 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $307.8M | 13 | 0001012975-26-000759 |
| 2026-03-31 | 2026-05-14 | $279.8M | 13 | 0001012975-26-000421 |
| 2025-12-31 | 2026-02-13 | $258.7M | 12 | 0001012975-26-000133 |
| 2025-09-30 | 2025-11-13 | $173.0M | 10 | 0001012975-25-000748 |
SAN FRANCISCO, CA 94107